Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

Cowen Maintains Positive View on Axsome Therapeutics (AXSM) Despite PDUFA Delay

August 23, 2021 12:58 PM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and $125.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the FDA informed the company last Friday that the Agency would not complete the review of the NDA submission regarding AXS-05 in MDD by the target PDUFA... More